Molecular Partners AG (MOLN)
4.00
+0.13
(+3.36%)
USD |
NASDAQ |
May 02, 16:00
4.00
0.00 (0.00%)
After-Hours: 18:09
Molecular Partners Cash from Operations (TTM): -65.71M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -65.71M |
September 30, 2023 | -61.93M |
June 30, 2023 | -65.32M |
March 31, 2023 | -70.63M |
December 31, 2022 | 124.32M |
Date | Value |
---|---|
September 30, 2022 | 116.04M |
June 30, 2022 | 114.62M |
March 31, 2022 | 110.60M |
December 31, 2021 | -99.51M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-99.51M
Minimum
Dec 2021
124.32M
Maximum
Dec 2022
11.39M
Average
-61.93M
Median
Sep 2023
Cash from Operations (TTM) Benchmarks
AC Immune SA | -67.27M |
CRISPR Therapeutics AG | -260.38M |
Addex Therapeutics Ltd | -8.901M |
NLS Pharmaceutics Ltd | -13.51M |
MoonLake Immunotherapeutics | -42.78M |